TerSera Therapeutics LLC announced that The National Comprehensive Cancer Network Head and Neck Cancers Panel recommended the GnRH agonist goserelin for patients with recurrent, unresectable, or metastatic salivary gland tumors who were not eligible for surgery or radiation therapy.
/PRNewswire/ TerSera Therapeutics announced today a new sponsorship with the Carcinoid Cancer Foundation (CCF) and Alira Health to expand and optimize a.